Bristol-Myers Squibb Company

- The company plans to take on additional debt in 2024 to finance acquisitions of Karuna and RayzeBio. - They have a strong financial position with approximately $12.6 billion in cash and marketable securities as of the latest report. - The company plans to repay approximately $10 billion of debt over the next two years to improve leverage. - There is no mention of equity fundraising or new equity issuance in the provided transcript. - The plan focuses on maintaining strong operating margins, investing for growth, and returning cash to shareholders while managing debt. - Financing costs related to acquisitions are expected to be dilutive to earnings slightly but manageable. No current plans for equity fundraising were disclosed; debt issuance is planned and will be managed with subsequent repayments.

- The company is actively involved in business development, focusing on executing recently closed deals and continuing to seek bolt-on opportunities that make strategic and financial sense (Page 8). - They are also pursuing partnerships and licensing deals as part of their capital allocation strategy (Page 8). - Additional debt will be taken on to finance planned acquisitions of Karuna and RayzeBio; the company plans to repay approximately $10 billion of debt over the next two years to improve leverage (Page 2). - Operating expenses are expected to increase modestly due to Mirati acquisition costs and reallocation of costs as part of efficiency initiatives (Page 2). - Investments will continue to support growth products and launches, including strengthening vector supply for Breyanzi and preparing for launches like KarXT and subcutaneous Opdivo (Pages 4, 3). - They plan ongoing investment in new product launches and commercialization capabilities to accelerate growth (Page 3).

- 2024 revenue expected to increase in a low single-digit range on an underlying basis (excluding currency impact), reflecting confidence in growth portfolio momentum. - Growth portfolio sales, including Opdivo and newly launched products, anticipated to drive momentum; Opdivo growth to be more modest than last year with potential acceleration in H2 2024 from new indications. - Eliquis expected to deliver strong growth in the U.S. throughout 2024. - Reblozyl sales projected to maintain strength with expanding first-line MDS use, and international growth including Japan and expected EU approval. - Sotyktu revenues expected to grow with broader payer coverage (e.g., ESI, Cigna), improved access, and prescription volume rising—aiming for roughly 20,000 prescriptions in Q4 2024, with continued volume momentum into 2025. - Breyanzi sales expected to grow strongly starting Q2 2024, supported by improved supply and new indications. - Zeposia sales set for continued growth driven by increased demand in multiple sclerosis and ulcerative colitis. - Operating margin target at least 37% maintained with disciplined investments and efficiency initiatives.

- Bristol Myers Squibb expects revenue growth in the low single-digit range in 2024, driven by their growing portfolio. - Gross margin is projected around 74%, reflecting sales mix evolution and nonrecurrence of last year’s hedging gains. - Operating expenses are forecasted to increase in the low single-digit range, accounting for Mirati costs and efficiency initiatives. - The operating margin target remains at least 37%, focusing on operational efficiencies while investing for growth. - Other income and expense (OI&E) is expected to be about $250 million, including PD-1 royalty income and Mirati financing costs. - The tax rate is projected at approximately 17.5%, due to prior tax benefits not recurring and new Pillar 2 impacts. - Non-GAAP earnings per share (EPS) guidance for 2024 is between $7.10 and $7.40, excluding impacts from pending acquisitions. - Acquisitions of Karuna and RayzeBio are expected to be dilutive to EPS by approximately $0.43 combined in 2024.

- Sotyktu orders showed normalized sales increased about 40% versus Q3, excluding clinical trial orders. - Progress is being made converting patients from Bridge programs to commercial prescriptions. - Roughly 10,000 paid prescriptions for Sotyktu expected this year, aiming for around 20,000 in Q4 with continued volume growth into Q1. - Reblozyl is experiencing strong demand, particularly with progress in first-line MDS U.S. launch and recent approvals in Japan. - Camzyos has approximately 4,500 patients on commercial supply, adding ~1,000 patients per quarter. - Augtyro launched late November with initial wholesaler stocking. - Opdualag and other growth products showing robust sales momentum. - Company actively negotiating additional payer coverage to expand patient access and further boost demand. - No specific numeric figures provided on overall orderbook or pending orders, but strong volume growth and access improvements highlight positive momentum.